Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.23.1
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Basic and diluted numerator:          
Net loss attributable to iBio, Inc. $ (10,563) $ (7,191)   $ (18,100) $ (12,379)
Preferred stock dividends - iBio CMO Preferred Tracking Stock 0 (22)   0 (88)
Net loss available to iBio, Inc. stockholders (10,563) (7,213)   (18,100) (12,467)
Loss from discontinued operations (22,990) (4,729)   (33,583) (8,480)
Net loss available to iBio, Inc. stockholders $ (33,553) $ (11,942)   $ (51,683) $ (20,947)
Basic and diluted denominator:          
Weighted-average common shares outstanding - basic 9,807 8,715   9,324 8,715
Weighted-average common shares outstanding - diluted 9,807 8,715 8,715 9,324 8,715
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (1.08) $ (0.83)   $ (1.94) $ (1.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (1.08) (0.83) $ (1.43) (1.94) (1.43)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (2.34) (0.54)   (3.60) (0.97)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (2.34) (0.54) (0.97) (3.60) (0.97)
Per share amount basic (3.42) (1.37)   (5.54) (2.40)
Per share amount diluted $ (3.42) $ (1.37) $ (2.40) $ (5.54) $ (2.40)